Corporate & Securities

Joint Ventures, Strategic Alliances, Collaborations & Technology Transfer

When thinking about entering into a partnership to develop your company or your product line, it’s crucial to consider the business, financial, and legal implications. Whether you are a company or individual in the life sciences or technology industry, you need counsel who is familiar with the ins and outs of your business so you can benefit from the most solidly structured agreement possible.

Our attorneys are regarded as some of the most knowledgeable attorneys in negotiating agreements for joint venture and collaborative research; development, services, and university licensing arrangements; and other agreements to develop new products and technology. Our attorneys’ knowledge of business, communications, technology, and intellectual property law allows them to provide exceptional business-focused legal advice in these complicated transactions. We will work closely with you to structure and implement a transaction that builds upon your strengths and fills the gaps where needed.

Quick Facts


  • National Tier 1 ranking for Biotechnology Law by U.S. News & World Report and Best Lawyers in “Best Law Firms” (2011 – 2012)
  • Recognized for Global, North America, and Asia-Pacific licensing by BioPharm Insight in “Global League Tables of Advisors to Biotech and Pharma Licensing Agreements and M&A” (2010 – 2012); led the “Global Licensing League Tables of Legal Advisors” in Q2 2012 for deal value
  • Assist clients in bringing their products from the research laboratory to the commercial market
  • Structure and implement technology-based transactions
  • Completed more than 35 licensing / collaboration transactions since 2010, with an aggregate deal value of approximately $5 billion

Areas of Focus

  • Advertising issues
  • Business continuity and master recovery
  • Data security and privacy
  • Development and collaboration arrangements
  • Distributorship agreements
  • Establishment, sourcing, procurement, and Implementation of IT systems and services
  • In-licensing of technology from universities and research institutions
  • Intellectual property protection and enforcement programs
  • Internet transactions and Internet liability issues
  • Outsourcing transactions
  • Strategic alliances and joint ventures

Sort by: Name  Title  Office

Priya K. Agrawal

Priya K. Agrawal

Associate

212.692.6708

212.692.6869

617.348.3018

617.348.1742

Hannah C. Coman

Hannah C. Coman

Associate

617.348.1703

617.348.4716

617.348.1670

617.348.1797

Robert Duggan

Robert Duggan

Member

617.348.1780

+44.20.7776.7330

617.348.1650

617.348.1654

Sarah T. Hogan

Sarah T. Hogan

Associate

617.348.1883

617.348.1638

858.314.1525

617.348.1732

Jessica D. Mendoza

Jessica D. Mendoza

Associate

415.432.6085

Tavis J. Morello

Tavis J. Morello

Associate

617.348.4464

Mark Nemes

Mark Nemes

Associate

212.692.6718

858.314.1873

617.348.3039

Anne L. Strassner

Anne L. Strassner

Of Counsel

212.692.6280

617.348.1869

617.348.1759

Representative Experience

  • Represented Inhibrx LLC in its June 2012 Option and License Agreement with Celgene Corporation.
  • Represented GreatPoint Energy, Inc. in its March 2012 $400 million Series D financing led by China Wanxiang Holding Co. Ltd.
  • Represented Angiochem, Inc. in its February 2012 collaboration with GlaxoSmithKline (GSK).
  • Represented Intarcia Therapeutics, Inc. in its December 2011 strategic alliance with Quintiles.
  • Represented ArQule, Inc. (NASDAQ: ARQL) in the November 2011 execution of a license agreement with Daiichi Sankyo, Co. Ltd.
  • Represented BeiGene, LLC on the exclusive in-licensing and co-development agreements of October 2011 with Janssen Pharmaceutica NV and CNA Development, LLC, divisions of Johnson & Johnson (NYSE: JNJ).